Anthranilamide

Anthranilamide

SCHEMBL4012579

NC(=O)c1cc(F)ccc1N.NC(=O)c1ccccc1N

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.59
IKBKB O14920 1/20 0.54
FADS1 O60427 2/20 0.46
MAPT P10636 2/20 0.43
PARP1 P09874 1/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CFTR P13569 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
AGTR1 P30556 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
STAT3 P40763 1/20 0.41
JAK3 P52333 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31230207 0.91 KEAP1 (0.70) KEAP1IKBKBFADS1MAPTPARP1
SCHEMBL183930 0.91 KEAP1 (0.70) KEAP1IKBKBFADS1MAPTPARP1
Hydrochloric Acid SCHEMBL4362930 0.89 KEAP1 (0.68) KEAP1IKBKBFADS1MAPTPARP1
Anthranilamide SCHEMBL7650571 0.82 HSD17B10 (0.58) IKBKBMAPTPARP1GAAALDH1A1
Anthranilamide SCHEMBL2801971 0.82 HSD17B10 (0.58) IKBKBMAPTPARP1GAAALDH1A1
Anthranilamide SCHEMBL7655669 0.82 HSD17B10 (0.58) IKBKBMAPTPARP1GAAALDH1A1
Anthranilamide SCHEMBL29391044 0.82 HSD17B10 (0.58) IKBKBMAPTPARP1GAAALDH1A1
Anthranilamide SCHEMBL38228 0.82 HSD17B10 (0.58) IKBKBMAPTPARP1GAAALDH1A1
Anthranilamide SCHEMBL8895450 0.80 HSD17B10 (0.56) IKBKBMAPTPARP1GAAALDH1A1
Anthranilamide SCHEMBL3196253 0.80 HSD17B10 (0.56) IKBKBMAPTPARP1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
CN-101068794-A Quinazolines useful as modulators of ion channels VERTEX PHARMA (US) 2007-11-07 CN disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 KEAP1 636/4885IKBKB 3409/4885FADS1 2511/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 KEAP1 636/4885IKBKB 3409/4885FADS1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.